CL2017002449A1 - Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas - Google Patents

Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas

Info

Publication number
CL2017002449A1
CL2017002449A1 CL2017002449A CL2017002449A CL2017002449A1 CL 2017002449 A1 CL2017002449 A1 CL 2017002449A1 CL 2017002449 A CL2017002449 A CL 2017002449A CL 2017002449 A CL2017002449 A CL 2017002449A CL 2017002449 A1 CL2017002449 A1 CL 2017002449A1
Authority
CL
Chile
Prior art keywords
prevention
treatment
bacterial infections
heterocyclic compounds
compounds
Prior art date
Application number
CL2017002449A
Other languages
English (en)
Inventor
Strat Frédéric Le
Sophie Chasset
Julie Brias
Audrey Caravano
Fabien Faivre
Sophie Vomscheid
Francis Chevreuil
Benoît Ledoussal
Sébastien Richard
Christophe Simon
Original Assignee
Mutabilis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP15305479.6A external-priority patent/EP3075734A1/en
Application filed by Mutabilis filed Critical Mutabilis
Publication of CL2017002449A1 publication Critical patent/CL2017002449A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS HETEROCÍCLICOS DE FÓRMULA (I), SU PROCEDIMIENTO DE PREPARACIÓN, COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN ESTOS COMPUESTOS Y EL USO DE LAS MISMAS, OPCIONALMENTE EN COMBINACIÓN CON OTROS AGENTES ANTIBACTERIANOS Y/O COMPUESTOS BETA-LACTÁMICOS, PARA LA PREVENCIÓN O TRATAMIENTO DE LAS INFECCIONES BACTERIANAS. LA PRESENTE INVENCIÓN TAMBIÉN SE REFIERE AL USO DE ESTOS COMPUESTOS COMO INHIBIDORES DE Β- LACTAMASA Y/O COMO AGENTES ANTIBACTERIANOS.</p>
CL2017002449A 2015-03-31 2017-09-28 Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas CL2017002449A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15305479.6A EP3075734A1 (en) 2015-03-31 2015-03-31 Heterocyclic compounds and their use in preventing or treating bacterial infections
EP16305059 2016-01-22

Publications (1)

Publication Number Publication Date
CL2017002449A1 true CL2017002449A1 (es) 2018-04-20

Family

ID=55642466

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002449A CL2017002449A1 (es) 2015-03-31 2017-09-28 Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas

Country Status (14)

Country Link
US (1) US10570131B2 (es)
EP (1) EP3277685B1 (es)
JP (1) JP2018510190A (es)
KR (1) KR20170131687A (es)
CN (1) CN107438610A (es)
AU (1) AU2016239207A1 (es)
BR (1) BR112017020826A2 (es)
CA (1) CA2980109A1 (es)
CL (1) CL2017002449A1 (es)
HK (1) HK1244791A1 (es)
MX (1) MX2017012539A (es)
RU (1) RU2715058C2 (es)
TW (1) TW201639853A (es)
WO (2) WO2016156344A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3300736B1 (en) * 2016-09-30 2021-05-05 Mutabilis Composition comprising antibiotic compound and an heterocyclic compound and their use in preventing or treating bacterial infections
EP3357924A1 (en) 2017-02-06 2018-08-08 Mutabilis Novel heterocyclic compounds and their use in preventing or treating bacterial infections
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
KR102790878B1 (ko) 2018-08-09 2025-04-02 앤타바이오 에스에이에스 세린 베타-락타마제의 억제제로서 다이아자바이사이클로옥타논

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY162532A (en) 2008-01-18 2017-06-15 Merck Sharp & Dohme Beta-lactamase inhibitors
KR101512738B1 (ko) * 2011-08-27 2015-04-17 욱크하르트 리미티드 1,6-디아자-비시클로[3,2,1]옥탄-7-온 유도체 및 세균 감염 치료에서의 그 유도체의 용도
KR101618424B1 (ko) 2011-08-30 2016-05-04 욱크하르트 리미티드 1,6-디아자비시클로[3,2,1]옥탄-7-온 유도체 및 세균 감염 치료에서의 그 유도체의 용도
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
AR091222A1 (es) 2012-05-30 2015-01-21 Meiji Seika Pharma Co Ltd INHIBIDOR DE b-LACTAMASA Y PROCESO PARA PREPARARLO
US9271446B2 (en) * 2012-06-28 2016-03-01 Forage Innovations B.V. Self-aligning apparatus and methods for gathering bales
CA2881169C (en) * 2012-08-25 2020-06-16 Wockhardt Limited 1,6-diazabicyclo [3,2,1]octan - 7 - one derivatives and their use in the treatment of bacterial infections
CN104994860A (zh) 2013-02-06 2015-10-21 阿斯利康(瑞典)有限公司 用于治疗医院性肺炎的组合疗法
WO2014141132A1 (en) * 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
EP3277267B1 (en) 2015-03-31 2021-01-06 Laboratorios Bagó S.A. Enteric-coated pellets containing a proton pump inhibitor
MA41850A (fr) 2015-03-31 2018-02-06 Takeda Pharmaceuticals Co Nouvelles utilisations pharmaceutiques
EP3075733A1 (en) 2015-03-31 2016-10-05 Mutabilis Novel heterocyclic compounds and their use in preventing or treating bacterial infections
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
EP3075734A1 (en) * 2015-03-31 2016-10-05 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections

Also Published As

Publication number Publication date
KR20170131687A (ko) 2017-11-29
RU2017133745A (ru) 2019-03-28
EP3277685A1 (en) 2018-02-07
CA2980109A1 (en) 2016-10-06
RU2017133745A3 (es) 2019-09-09
WO2016156344A1 (en) 2016-10-06
WO2016156346A1 (en) 2016-10-06
HK1244791A1 (zh) 2018-08-17
RU2715058C2 (ru) 2020-02-25
JP2018510190A (ja) 2018-04-12
TW201639853A (zh) 2016-11-16
MX2017012539A (es) 2018-09-28
AU2016239207A1 (en) 2017-10-12
CN107438610A (zh) 2017-12-05
EP3277685B1 (en) 2021-01-13
BR112017020826A2 (pt) 2018-07-03
US10570131B2 (en) 2020-02-25
US20180086760A1 (en) 2018-03-29

Similar Documents

Publication Publication Date Title
CL2017002482A1 (es) Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
MX2021009673A (es) Moduladores de ror-gamma.
CL2014001956A1 (es) Compuestos derivados de beta-lactamicos sustituidos con amidina; metodo para su preparacion; medicamento que los comprende; y su uso para el tratamiento y/o profilaxis de infecciones bacterianas.
BR112018003026A2 (pt) composições compreendendo um inibidor de pi3k e um inibidor de hdac
CU20160149A7 (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
MX381488B (es) Indoles para su uso en la infección por el virus de la gripe.
CL2020001147A1 (es) Compuestos antibacterianos
DOP2016000125A (es) MODULADORES DE ROR GAMMA (RORy)
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CL2017002451A1 (es) Compuestos heterocíclicos novedosos y su uso en la prevención o tratamiento de las infecciones bacterianas
CL2012001821A1 (es) Compuestos derivados de 5-alquinil-pirimidinas, inhibidores de quinasas; composiciones farmaceuticas que los contienen; y su uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
CL2016000568A1 (es) Compuestos derivados de 2h-indazol-2-il-n-hidroxi-2-metilsulfonil-2-metil-butanamida sustituidos o sus sales; sus composiciones farmacéuticas que los contiene y su uso para la prevención y/o tratamiento de infecciones bacterianas gram-negativas.
CL2017002803A1 (es) Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
EA201892822A1 (ru) Новые антибактериальные соединения
MX373320B (es) Compuestos inhibidores de pde2.
MX2017014459A (es) Compuestos de tioeter como inhibidores de la nitrificacion.
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
DOP2019000221A (es) Derivados de pirazol como inhibidores de bromodominio
CR20150417A (es) Compuestos de azetidiniloxifenilpirrolidina
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
PL3618826T3 (pl) Kompozycje do leczenia zakażeń patogenami
KR101675359B9 (ko) 네오아가로올리고당을 유효성분으로 포함하는 패혈증 또는 패혈증성 쇼크의 예방 또는 치료용 조성물
CL2017001276A1 (es) Derivados de benzotiazol antibacterianos